Canaccord Genuity has advised SEQENS, an SK Capital-backed company, on entering exclusive negotiations with Novartis France for the potential acquisition of CELLforCURE and its production site located in France (Les Ulis)
We are pleased to announce that Canaccord Genuity has advised SEQENS SAS (“SEQENS”), a portfolio company of SK Capital, on entering exclusive negotiations with Novartis France for the potential acquisition of CELLforCURE and its production site located in France (Les Ulis). CELLforCURE’s site in Les Ulis was inaugurated 10 years ago and specialises in the development and custom production of cell & gene therapies.
SEQENS is a world leader in the development and production of active pharmaceutical ingredients, intermediates and specialty ingredients, with 24 production sites, 10 R&D centers and 3,400 employees on 3 continents. An integrated player across the entire value chain - from raw materials to active ingredients and from R&D to industrialization - SEQENS offers a broad portfolio of active ingredients, pharmaceutical intermediates and specialty ingredients and chemicals, develops and industrializes the most complex molecules, and leverages its ability to innovate, develop and implement the best available technologies.
With this contemplated acquisition, SEQENS has the ambition to bring all its industrial expertise and investment capacity with the aim of ensuring the company's long-term future, maintaining the recognized cell therapy skills of CELLforCURE's teams in France, completing its industrial facilities and pharmaceutical solutions offering, and strengthening its position as a leader in the development and production of essential medicines.